- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
What side effects of CAR T therapies are currently known?
Primary side effects of CAR T therapies occur early on after treatment and they’re related to the growth of the T cells and the actual activity of the T cells. So many patients will have fever and potentially progressing to more serious symptoms requiring hospital-level care and sometimes ICU-level care. Those symptoms typically resolve within the first week or sometimes within the first several weeks.
The main side effects of this therapy are within the first 28 days. But there’s lots of monitoring and potential for long-term side effects as well. Most patients are usually physically very well after the first month of treatment, but still require some focused monitoring for some of the on-target effects of CAR T cells, which involve B-cell aplasia. So, these patients, because of how CD19 CAR T cells work, will be depleted of their normal B cells, and that requires monitoring and replacement of the immunoglobulin long term.
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
March 10th 2025The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, that has been made in the fight against the HIV pandemic given the current political climate.
Read More
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More
